Abstract |
Pure allicin, prepared biosynthetically by reacting synthetic alliin with an immobilized alliinase enzyme, is known to possess cardioprotective effects. However, in its pure form, allicin is pharmacologically unstable. S-allylmercaptocaptopril ( CPSSA) is a new stable synthetic compound produced by chemical reaction between allicin and the angiotensin converting enzyme inhibitor captopril. Using the fructose-induced metabolic syndrome rat model we studied the effects of short-term treatment with two doses of CPSSA on cardiovascular risk factors associated with the metabolic syndrome, in comparison to the effects of allicin and captopril separately. Allicin (8 mg/(kg day)) significantly reduced insulin, triglycerides, and homocysteine concentrations, and had a slight effect on SBP. Captopril (50mg/(kg day)) only improved blood pressure and homocysteine. Treatment with low dose of CPSSA (5mg/(kg day)) lowered SBP but did not improve any other measured parameter, while treatment with a higher dose (50mg/(kg day)) significantly decreased blood pressure, triglycerides, and homocysteine concentrations. We conclude that the combined molecule CPSSA integrates the anti-hypertensive, lipid-lowering, and homocysteine-reducing effects of both allicin and captopril, making it a potential cardiovascular protective agent.
|
Authors | Mor Oron-Herman, Talma Rosenthal, David Mirelman, Talia Miron, Aharon Rabinkov, Meir Wilchek, Ben-Ami Sela |
Journal | Atherosclerosis
(Atherosclerosis)
Vol. 183
Issue 2
Pg. 238-43
(Dec 2005)
ISSN: 0021-9150 [Print] Ireland |
PMID | 16285991
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antihypertensive Agents
- Cyclopropanes
- Disulfides
- Hypoglycemic Agents
- Insulin
- Sulfinic Acids
- Triglycerides
- Homocysteine
- 1-formylcyclopropane-2-carboxylic acid
- allicin
- Captopril
|
Topics |
- Animals
- Antihypertensive Agents
(chemistry, therapeutic use)
- Blood Pressure
(drug effects)
- Captopril
(chemistry, therapeutic use)
- Cyclopropanes
(chemical synthesis, therapeutic use)
- Disease Models, Animal
- Disulfides
- Homocysteine
(blood, drug effects)
- Hypertension
(blood, etiology, prevention & control)
- Hypoglycemic Agents
(chemistry, therapeutic use)
- Insulin
(blood)
- Male
- Metabolic Syndrome
(blood, complications, drug therapy)
- Rats
- Rats, Sprague-Dawley
- Risk Factors
- Sulfinic Acids
(chemistry, therapeutic use)
- Treatment Outcome
- Triglycerides
(blood)
|